PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis

Description: PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis

Summary

GlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The US influenza vaccine market is valued at approximately $1.05 billion in 2012. The projected drivers for market growth include increased patient awareness on the importance of being vaccinated against influenza, the introduction of vaccines with a quadrivalent formulation, a growing elderly population, and introduction of vaccines with improved efficacy in elderly patients.

Sanofi is the current market leader. It was among the first influenza vaccines available in the US, and it has produced a diverse portfolio of influenza vaccines under Sanofi's Fluzone brand. This brand includes trivalent vaccines with novel routes of administration (Fluzone ID) and vaccines with enhanced immunogenicity in elderly recipients (Fluzone High-Dose).

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
9.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Leading Influenza Vaccines, 2012
Table 5: Product Profile - Fluzone
Table 6: Fluzone SWOT Analysis, 2012
Table 7: Product Profile - Fluarix
Table 8: Fluarix SWOT Analysis, 2012
Table 9: Product Profile - Fluvirin
Table 10: Immunogenicity of Agrippal and Fluvirin
Table 11: Fluvirin SWOT Analysis, 2012
Table 12: Product Profile - FluMist
Table 13: FluMist SWOT Analysis, 2012
Table 14: Product Profile - Afluria
Table 15: Afluria SWOT Analysis, 2012
Table 16: Product Profile - Fluad
Table 17: Fluad SWOT Analysis, 2012
Table 18: Product Profile - Fluzone High-Dose
Table 19: Non-inferiority comparison of Fluzone High-Dose and Standard-Dose Vaccines
Table 20: Fluzone High-Dose SWOT Analysis, 2012
Table 21: Product Profile - Fluzone ID
Table 22: Non-inferiority Comparison of Fluzone ID and IM Vaccines
Table 23: Fluzone ID SWOT Analysis, 2012
Table 24: Product Profile - Optaflu
Table 25: Optaflu SWOT Analysis, 2012
Table 26: Overall Unmet Needs - Current Level of Attainment
Table 27: Clinical Unmet Needs - Gap Analysis, 2012
Table 28: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 29: Product Profile - FluBlok
Table 30: FluBlok SWOT Analysis, 2012
Table 31: Product Profile - Influenza VLP Vaccine
Table 32: Influenza VLP Vaccine SWOT Analysis, 2012
Table 33: Sales Forecasts ($m) for Influenza Vaccines in the United States, 2012-2022
Table 34: Key Events Impacting Sales of Influenza Vaccines in US, 2012
Table 35: Influenza Vaccine Market - Drivers and Barriers, 2012
Table 36: Key Launch Dates
Table 37: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022
Figure 3: Sales for Influenza Vaccines in the United States by Route of Administration, 2012-2022

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2368659/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2368659/">http://www.researchandmarkets.com/reports/2368659/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6I5RW4</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Site License</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:

Research and Markets,  
Guinness Center,  
Taylors Lane,  
Dublin 8,  
Ireland.

☐ Pay by wire transfer:  Please transfer funds to:

Account number 833 130 83  
Sort code 98-53-30  
Swift code ULSBIE2D  
IBAN number IE78ULSB98533083313083  
Bank Address Ulster Bank,  
27-35 Main Street,  
Blackrock,  
Co. Dublin,  
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA  
+353-1-481-1716 or +353-1-653-1571 - From Rest of World